Citius Pharmaceuticals, Inc. (CTXR) is a cutting-edge biopharmaceutical company that focuses on the development and commercialization of critical care products, primarily in the therapeutic areas of oncology, anti-infectives, and the central nervous system. The company has a firm commitment towards providing innovative and effective solutions to improve the health and quality of life of patients worldwide.
Founded in 2007 and based in Cranford, New Jersey, Citius Pharmaceuticals has consistently demonstrated its unwavering commitment to research and development. This dedication is evident in its rich product pipeline featuring innovative drug candidates designed to address unmet medical needs, thereby enhancing treatment options and patient outcomes.
One of their notable product candidates is Mino-Lok®, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). Mino-Lok® is currently in a pivotal Phase 3 clinical trial, after having received the FDA’s QIDP (Qualified Infectious Disease Product) designation and Fast Track designation, indicating its potential significance in the medical field.
Another promising candidate in their pipeline is the CITI-002, a topical formulation of hydrocortisone and lidocaine intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. This gel formulation aims to be the first FDA-approved prescription product to treat hemorrhoids in the U.S.
Furthermore, Citius Pharmaceuticals is also developing CITI-101 (Mino-Wrap), a liquefying gel-based wrap containing minocycline and rifampin for reducing tissue expander (TE) infections following breast reconstructive surgeries.
Citius Pharmaceuticals operates with a clear vision for the future, upholding its mission to serve patients by creating first-rate, cost-effective therapeutics. Leveraging its scientific research, the company is constantly paving the way for novel therapy routes and fostering innovative thinking to stay at the forefront of pharmaceutical advancements.
Furthermore, the company maintains a robust governance structure emphasizing transparency and ethical business operations. It underscores the importance of its stakeholders, ensuring that it makes decisions in the best interest of the company and its shareholders.
With a balanced strategy of in-house development and strategic partnerships, Citius Pharmaceuticals is poised for significant growth and progression in the biopharmaceutical industry. The company's ethos, coupled with its innovative research, product pipeline, and the unwavering commitment to patients and medical practitioners, makes Citius Pharmaceuticals a noteworthy player in the global pharmaceutical industry.